Potassium Magnesium Aspartate Tablets

(1) Pharmacology Aspartic acid (Asp), also known as aspartic acid, contains two carboxyl groups and one amino group in its molecule. It is an acidic amino acid and is widely present in all proteins. Aspartic acid is a precursor of oxaloacetate and plays an important role in the tricarboxylic acid cycle, ornithine cycle and nucleotide synthesis. It has a strong affinity for cells and can be used as a carrier to facilitate the entry of potassium ions and magnesium ions into the cytoplasm and mitochondria to maintain the normal excitability and stability of the internal environment of cells such as nerve tissue, myocardium and smooth muscle. It transports electrolytes to the myocardium, promotes myocyte depolarization, maintains myocardial contractility, and reduces myocardial oxygen consumption. It has a protective effect on the myocardium when hypoxia is caused by coronary circulation disorders. Aspartic acid participates in the ornithine cycle, promotes urea production, reduces the content of ammonia and carbon dioxide in the blood, and enhances liver function. (2) Toxicology This product has very low toxicity. Mice fed with 2g/(kg·day) had no toxic reactions for 6 months, and mice fed with 400 times the adult dose did not die.

Each tablet of this product contains 158 mg of potassium aspartate (C4H6NO4K) and 140 mg of magnesium aspartate [(C4Hshy;6NO4)2Mg].

This product is a white tablet.

Electrolyte supplement. Suitable for hypokalemia, improving symptoms of poisoning such as arrhythmia, nausea, vomiting caused by digitalis poisoning, for various heart diseases such as sequelae of myocarditis and chronic heart failure, and can also be used as an auxiliary treatment for acute and chronic hepatitis, cirrhosis, bile secretion deficiency and hepatic encephalopathy. (1) Auxiliary treatment of cardiovascular system diseases, including: ① arrhythmia and tachycardia caused by various reasons in adults and children, as well as arrhythmia caused by digitalis poisoning; ② myocardial infarction, coronary heart disease, angina pectoris, hypertension, etc.; ③ myocardial damage caused by tumor chemotherapy. (2) Digestive system diseases Auxiliary treatment of various liver diseases such as acute and chronic hepatitis, jaundice, cirrhosis, hepatic coma, drug-induced liver damage (including tumor chemotherapy). (3) Auxiliary treatment of respiratory system diseases such as bronchial asthma, chronic obstructive pulmonary disease and chronic cor pulmonale. (4) Auxiliary treatment of nervous system diseases such as stroke, ischemic cerebrovascular disease, Japanese encephalitis, acute craniocerebral injury, peripheral nerve paralysis, etc. (5) Auxiliary treatment for metabolic diseases such as hypokalemia, hypomagnesemia, diabetes, and metabolic disorders in surgical patients. (6) Auxiliary treatment for other conditions such as pregnancy vomiting, pregnancy poisoning, immunosuppression, extracorporeal circulation heart surgery, fatigue, hearing loss, etc.

Oral administration, 1 tablet at a time, 3 times a day.

Nausea may occur occasionally, but will resolve after medication is discontinued.

It is contraindicated in patients with hyperkalemia, hypermagnesemia, severe renal dysfunction and severe atrioventricular block.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

It should not be used in combination with potassium-sparing diuretics.

Store in a sealed container away from light.

Each tablet contains 79 mg of anhydrous potassium aspartate and 70 mg of anhydrous magnesium aspartate

24 months

Zhejiang Zhongyi Pharmaceutical Co., Ltd.

• Founded in:

  2006-01-26

• Address:

  No. 279, Lvgu Avenue, Shuige Industrial Zone, Zhejiang Province

• Tax NO.:

  91331100773112151W

• Registered Funds:

  40.5 million yuan

• Email:

  Log in to view